Comparative phenotypic, functional, and molecular analysis of pluripotent stem cells arguably the most significant challenge in stem cell biology today is determining whether human induced pluripotent stem cells (hiPSC) are truly equivalent to human embryonic stem cells (hESC), and thus can serve as a stable, safe, and less controversial resource for basic research and cell replacement therapies. Although the evidence to date suggests that murine ESC and iPSC are functionally interchangeable, the analysis is preliminary and incomplete, especially for human cells, and evidence is accumulating that important molecular differences distinguish the two types of pluripotent stem cells. To answer whether significant functional and molecular differences exist, we have assembled an outstanding cohort of collaborators, each with unique and complementary expertise, to perform a comprehensive phenotypic, functional, and molecular comparison of multiple ESC and iPSC lines using genomic, epigenetic, proteomic, computational, and pathologic analysis. In recent years, the Daley lab has simultaneously pursued derivation of novel hESC from discarded IVF embryos and generation of hiPSC by direct somatic cell reprogramming. Moreover, we have an extensive collection of murine pluripotent stem cells generated by direct reprogramming (miPSC) or isolated from embryos after fertilization (fESC), parthenogenesis (pESC), and somatic cell nuclear transfer (ntESC). This comprehensive set of reagents affords us a unique opportunity to test the hypothesis that iPSC are the functional equivalents of ESC in assays of pluripotency, but that molecular differences persist between the two classes of pluripotent stem cells. We will further test the hypothesis that differences between ESC and iPSC are largely due to residual transgene expression in iPSC, and will resolve once transgenes are removed. However, preliminary data suggests that even transgene-free iPSC are epigenetically distinct from ESC. Thus, an alternative hypothesis is that factor-based reprogramming leaves a residual epigenetic signature of the tissue of origin (""""""""epigenetic memory""""""""), and that the reprogramming process confers unique molecular features on iPSC. In addition to comparing and contrasting ESC and iPSC, our analysis will illuminate the degree of variation among independent clones of ESC and iPSC. Defining the extent of functional similarity, assessing the nature of any molecular differences, and defining biomarkers of the successfully reprogrammed state are key goals of this proposal. Insights gleaned herein will contribute to improved reprogramming methods, thereby facilitating the application of iPSCs to disease research and cell therapies.

Public Health Relevance

Pluripotent stem cells offer tremendous promise as tools for basic biomedical research, disease modeling and drug screening, and provide a means of deriving patient-specific rejection-proof cells that might be used in cell replacement therapies for a large number of genetic, malignant, and degenerative diseases. Techniques for establishing """"""""induced pluripotent stem"""""""" or """"""""iPS"""""""" cells fulfill the long-sought strategy for generating customized stem cells. If proven equivalent-both functionally and molecularly-to blastocyst-derived human embryonic stem cells, iPS cells will facilitate research, quell contentious public debate, and yield a new modality for tissue repair and regeneration.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
High Impact Research and Research Infrastructure Programs (RC2)
Project #
5RC2HL102815-02
Application #
7941821
Study Section
Special Emphasis Panel (ZHL1-CSR-W (O3))
Program Officer
Thomas, John
Project Start
2009-09-30
Project End
2012-02-29
Budget Start
2010-09-01
Budget End
2012-02-29
Support Year
2
Fiscal Year
2010
Total Cost
$1,683,978
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Lee, Je Hyuk; Daugharthy, Evan R; Scheiman, Jonathan et al. (2015) Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat Protoc 10:442-58
Lee, Je Hyuk; Daugharthy, Evan R; Scheiman, Jonathan et al. (2014) Highly multiplexed subcellular RNA sequencing in situ. Science 343:1360-3
Lu, Yu; Loh, Yuin-Han; Li, Hu et al. (2014) Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. Cell Stem Cell 15:92-101
Cherry, Anne B C; Daley, George Q (2013) Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med 64:277-90
Apostolou, Effie; Ferrari, Francesco; Walsh, Ryan M et al. (2013) Genome-wide chromatin interactions of the Nanog locus in pluripotency, differentiation, and reprogramming. Cell Stem Cell 12:699-712
Shyh-Chang, Ng; Locasale, Jason W; Lyssiotis, Costas A et al. (2013) Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 339:222-6
Cahan, Patrick; Daley, George Q (2013) Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol 14:357-68
Lengerke, Claudia; Daley, George Q (2012) Caudal genes in blood development and leukemia. Ann N Y Acad Sci 1266:47-54
Daley, George Q (2012) The promise and perils of stem cell therapeutics. Cell Stem Cell 10:740-749
McKinney-Freeman, Shannon; Cahan, Patrick; Li, Hu et al. (2012) The transcriptional landscape of hematopoietic stem cell ontogeny. Cell Stem Cell 11:701-14

Showing the most recent 10 out of 25 publications